[HTML][HTML] Clinical manifestations, diagnosis, and treatment of sarcoidosis

P Ungprasert, JH Ryu, EL Matteson - Mayo Clinic Proceedings: Innovations …, 2019 - Elsevier
The focus of this review is current knowledge about the epidemiology, clinical
manifestations, diagnosis, and treatment of both pulmonary sarcoidosis and extrapulmonary …

Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions

I Klaassen, CJF Van Noorden… - Progress in retinal and …, 2013 - Elsevier
Breakdown of the inner endothelial blood-retinal barrier (BRB), as occurs in diabetic
retinopathy, age-related macular degeneration, retinal vein occlusions, uveitis and other …

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked …

QD Nguyen, PT Merrill, GJ Jaffe, AD Dick, SK Kurup… - The Lancet, 2016 - thelancet.com
Background Non-infectious uveitis is a potentially sight-threatening ocular disorder caused
by chronic inflammation and its complications. Therapeutic success is limited by systemic …

Expert panel recommendations for the use of anti–tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

G Levy-Clarke, DA Jabs, RW Read, JT Rosenbaum… - Ophthalmology, 2014 - Elsevier
Topic To provide recommendations for the use of anti-tumor necrosis factor α (TNF-α)
biologic agents in patients with ocular inflammatory disorders. Clinical Relevance Ocular …

Ocular sarcoidosis

S Pasadhika, JT Rosenbaum - Clinics in chest medicine, 2015 - chestmed.theclinics.com
Ocular involvement of sarcoidosis has been known since the early 1900s and has become
more recognized since the mid-1900s. 1 Variability in the diagnostic criteria has made …

Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment

L Du, A Kijlstra, P Yang - Progress in retinal and eye research, 2016 - Elsevier
Abstract Vogt-Koyanagi-Harada (VKH) disease is one of the major vision-threatening
diseases in certain populations, such as Asians, native Americans, Hispanics and Middle …

Understanding uveitis: the impact of research on visual outcomes

MD de Smet, SRJ Taylor, B Bodaghi… - Progress in retinal and …, 2011 - Elsevier
The term uveitis encompasses a very diverse group of inflammatory ocular diseases that
cause a significant burden of legal and economic blindness. Indeed, the socioeconomic …

Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive …

É Toussirot, F Aubin - RMD open, 2016 - rmdopen.bmj.com
Paradoxical adverse events (PAEs) have been reported during biological treatment for
chronic immune-mediated diseases. PAEs are defined as the occurrence during biological …

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

A Arida, K Fragiadaki, E Giavri, PP Sfikakis - Seminars in arthritis and …, 2011 - Elsevier
OBJECTIVE:: Off-label use of anti-tumor necrosis factor (TNF) agents for Behçet's disease
(BD) is increasing. We evaluated published data on their efficacy and safety for patients with …

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis

S Pasadhika, JT Rosenbaum - Biologics: Targets and Therapy, 2014 - Taylor & Francis
Uveitis is one of the leading causes of blindness worldwide. Noninfectious uveitis may be
associated with other systemic conditions, such as human leukocyte antigen B27-related …